
The odyssey towards metastatic breast cancer survival: The AURORA academic research programme
4 June marks National Cancer Survivors Day (in the US) – a moment to recognise
4 June marks National Cancer Survivors Day (in the US) – a moment to recognise
The latest edition of BIG Research in Focus highlights the POSITIVE trial. Clic here to discover it.
This Saturday, on the 20th of May, the world will come together to mark International
The HERA study: a new standard of care for HER2-positive breast cancer The HERA study,
At this year’s St. Gallen Breast Cancer Congress (SGBCC, 15-18 March 2023), Professor Giuseppe Viale
Results of the final analysis of the NeoALTTO study have been published in the European
The results of the combined SOFT-TEXT analysis after 13 years of follow-up are now published in the Journal of Clinical Oncology
4 February = WORLD CANCER DAY Theme 2023: “Close the care gap” The POSITIVE –
On 7 December, a spotlight poster discussion on male breast cancer, including the work of
Pausing endocrine treatment to try to get pregnant can be done without additional risk of
On Thursday 29 September, the Breast International Group had the honour of hosting its Honorary President, Her Royal Highness the Queen of the Belgians, around a round table session with over 40 influential people from the Belgian Business world.
“MISSING” is an awareness initiative of the Breast International Group (BIG) to remember those women
The unmet needs of older patients with breast cancer The themed article of this edition
At the recent ASCO Annual Meeting 2022 Dr Etienne Brain received the B.J. Kennedy Geriatric
New Orleans, U.S.A. – Yesterday at the AACR Annual Meeting 2022 Dr Martine Piccart received the Victoria’s Secret Global Fund for Women’s Cancers 2022 Meritorious Award
In July 2021, we shared with you the first encouraging results from BIG’s OlympiA study. Updated results are even more encouraging.
On 17 March the first patient was randomised in the large AMEERA-6 trial, from a hospital in Chile.
The positive results of the PYTHIA trial were published on 14 February in the European Journal of Cancer.
Breast international group (BIG) – aisbl
Rue de Bretagne 20,
1200 Brussels, Belgium
VAT BE 0468 176 240
IBAN BE08 0689 0916 0213
Donations greater than or equal to € 40 / year receive a 45% tax reduction. This means your donation of €40 only costs you € 22.
The Breast International Group is proud to adhere
to the Code of Ethics of the VEF-AERF
Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
© 2022 All rights reserved
Breast international group (BIG) - aisbl